Attached files
file | filename |
---|---|
EX-10.41 - WARRANT AGENCY AGREEMENT - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex1041.htm |
EX-10.40 - PLACEMENT AGENCY AGREEMENT - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex1040.htm |
EX-5.1 - LEGAL OPINION - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex0501.htm |
EX-4.14 - FORM OF REPRESENTATIVE'S UNIT PURCHASE OPTION - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex0414.htm |
EX-4.13 - SERIES C COMMON STOCK WARRANT CERTIFICATE - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex0413.htm |
EX-3.12 - CERTIFICATE OF DESIGNATION - SERIES C CONVERTIBLE PREFERRED - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2-ex0312.htm |
S-1/A - FORM S-1 AMENDMENT - Sonoma Pharmaceuticals, Inc. | sonoma_s1a2.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the inclusion in this Registration Statement of Sonoma Pharmaceuticals, Inc. (the “Company”) on Amendment No. 2 to Form S-1 (File No. 333-227806) of our report dated June 26, 2018, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Sonoma Pharmaceuticals, Inc. and Subsidiaries as of March 31, 2018 and 2017 and for each of the two years in the period ended March 31, 2018, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum LLP
Marcum LLP
New York, NY
November 13, 2018